Acute Medium Chain Triglycerides (MCT) Intake in Young and Older Participants

Ketonemia Clinical Trial

— Opti-MCT  

Official title:

Optimisation of Acute Medium Chain Triglycerides Intake Characteristics on Different Plasma Metabolites in Young and Older Participants

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03830268
• Other study ID #: 2017-714
• Status: Completed
• Phase: N/A
• Start date: June 2, 2017
• Est. completion date: June 25, 2019

Study information

• Verified date: March 2020
• Source: Université de Sherbrooke
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Compare plasma metabolites following different conditions paired with a dietary MCT beverage over an 8-hour metabolic day protocol in young and older participants.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 20
• Est. completion date: June 25, 2019
• Est. primary completion date: June 25, 2019
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 20 Years and older

Eligibility

Inclusion Criteria:

• 10 health young (20-40 y old) and 10 health older (> 60 y old) participants

• Men and women

Exclusion Criteria:

• smoking

• diabetes (fasting glucose >7.0 mmol/l and glycated hemoglobin >6.9%)

• strenuous aerobic exercise more than three times a week

• untreated hypertension, dyslipidemia, and abnormal renal, liver, heart or thyroid function

• under medication known to affect triglycerides and carbohydrates metabolism (i.e. diuretics, beta-blockers, steroids, insulin sensitizing)

Related Conditions & MeSH terms

• Ketonemia
• Ketosis

Intervention

Dietary Supplement:
• No MCT intake with breakfast, no lunch
Water given with a regular standardize breakfast and water given at noon without lunch.
• No MCT intake with lunch, no breakfast
Water given in the beginning of the metabolic study day without breakfast and water given at noon with a regular standardize lunch.
• 10g of Betaquik
BQ10 given with a regular standardize breakfast and BQ10 given at noon without lunch.
• 10g of Betaquik with low-carbs breakfast
BQ10 given with a low-carbs standardize breakfast and BQ10 given at noon without lunch.
• 20g of Betaquik
BQ20 given with a regular standardize breakfast and BQ20 given at noon without lunch.
• 10g of Betaquik with lunch, no breakfast
BQ10 given in the beginning of the metabolic study day without breakfast and BQ10 given at noon with a regular standardize lunch.

Locations

Country	Name	City	State
Canada	Rearsh Centre on Aging	Sherbrooke	Quebec

Sponsors (1)

Lead Sponsor	Collaborator
Université de Sherbrooke

Country where clinical trial is conducted

Canada, 

References & Publications (5)

Castellano CA, Nugent S, Paquet N, Tremblay S, Bocti C, Lacombe G, Imbeault H, Turcotte É, Fulop T, Cunnane SC. Lower brain 18F-fluorodeoxyglucose uptake but normal 11C-acetoacetate metabolism in mild Alzheimer's disease dementia. J Alzheimers Dis. 2015;43(4):1343-53. doi: 10.3233/JAD-141074. — View Citation

Courchesne-Loyer A, Croteau E, Castellano CA, St-Pierre V, Hennebelle M, Cunnane SC. Inverse relationship between brain glucose and ketone metabolism in adults during short-term moderate dietary ketosis: A dual tracer quantitative positron emission tomography study. J Cereb Blood Flow Metab. 2017 Jul;37(7):2485-2493. doi: 10.1177/0271678X16669366. Epub 2016 Jan 1. — View Citation

Courchesne-Loyer A, Fortier M, Tremblay-Mercier J, Chouinard-Watkins R, Roy M, Nugent S, Castellano CA, Cunnane SC. Stimulation of mild, sustained ketonemia by medium-chain triacylglycerols in healthy humans: estimated potential contribution to brain energy metabolism. Nutrition. 2013 Apr;29(4):635-40. doi: 10.1016/j.nut.2012.09.009. Epub 2012 Dec 28. — View Citation

Croteau E, Castellano CA, Fortier M, Bocti C, Fulop T, Paquet N, Cunnane SC. A cross-sectional comparison of brain glucose and ketone metabolism in cognitively healthy older adults, mild cognitive impairment and early Alzheimer's disease. Exp Gerontol. 2018 Jul 1;107:18-26. doi: 10.1016/j.exger.2017.07.004. Epub 2017 Jul 12. — View Citation

Cunnane SC, Courchesne-Loyer A, St-Pierre V, Vandenberghe C, Pierotti T, Fortier M, Croteau E, Castellano CA. Can ketones compensate for deteriorating brain glucose uptake during aging? Implications for the risk and treatment of Alzheimer's disease. Ann N Y Acad Sci. 2016 Mar;1367(1):12-20. doi: 10.1111/nyas.12999. Epub 2016 Jan 14. Review. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Concentration of plasma ketones (acetoacetate and B-hydroxybutyrate)	To compare acute ketonemia following different conditions paired with a dietary MCT beverage over an 8-hour metabolic day protocol.	8 hours
Secondary	Concentration of plasma glucose	To compare acute glucose following different conditions paired with a dietary MCT beverage over an 8-hour metabolic day protocol.	8 hours
Secondary	Concentration of plasma insulin	To compare acute insulin following different conditions paired with a dietary MCT beverage over an 8-hour metabolic day protocol.	8 hours
Secondary	Concentration of plasma free fatty acids	To compare acute free fatty acids following different conditions paired with a dietary MCT beverage over an 8-hour metabolic day protocol.	8 hours